UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

Blood, 2019-09, Vol.134 (13), p.1024-1036

2019

Link zum Volltext

Verfügbarkeit prüfen

Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Molecular cancer therapeutics, 2017-07, Vol.16 (7), p.1246-1256

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

Clinical cancer research, 2010-01, Vol.16 (2), p.699-710

2010

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib‐associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma

British journal of haematology, 2015-07, Vol.170 (1), p.131-134

2015

Link zum Volltext

Verfügbarkeit prüfen

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma

Blood, 2017-04, Vol.129 (16), p.2224-2232

2017

Link zum Volltext

Verfügbarkeit prüfen

Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels

The Journal of pharmacology and experimental therapeutics, 2011-06, Vol.337 (3), p.636

2011

Link zum Volltext

Verfügbarkeit prüfen

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

The New England journal of medicine, 2013-08, Vol.369 (6), p.507-516

2013

Link zum Volltext

Verfügbarkeit prüfen

Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia

Clinical cancer research, 2006-01, Vol.12 (2), p.591-599

2006

Link zum Volltext

Verfügbarkeit prüfen

Characterization of a R115777-Resistant Human Multiple Myeloma Cell Line with Cross-Resistance to PS-341

Clinical cancer research, 2005-08, Vol.11 (16), p.6057-6064

2005

Link zum Volltext

Verfügbarkeit prüfen

A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors

Clinical cancer research, 2010-05, Vol.16 (9), p.2677-2687

2010

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors

Oncotarget, 2015-07, Vol.6 (21), p.18693-18706

2015

Link zum Volltext

Verfügbarkeit prüfen

RAS and Leukemia: From Basic Mechanisms to Gene-Directed Therapy

Journal of clinical oncology, 1999-03, Vol.17 (3), p.1071-1079

1999

Link zum Volltext

Verfügbarkeit prüfen

Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: Learnings from a survey of approved drugs

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e15648-e15648

2020

Link zum Volltext

Verfügbarkeit prüfen

Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells

Blood, 2005-06, Vol.105 (12), p.4759-4766

2005

Link zum Volltext

Verfügbarkeit prüfen

R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways

Molecular cancer therapeutics, 2004-02, Vol.3 (2), p.179-186

2004

Link zum Volltext

Verfügbarkeit prüfen

The Pan-Clk/Dyrk Inhibitor Cirtuvivint (SM08502) Exposes Mechanistic Underpinnings of Alternative Splicing As a Therapeutic Vulnerability in Heme Malignancies

Blood, 2021-11, Vol.138 (Supplement 1), p.2950-2950

2021

Link zum Volltext

Verfügbarkeit prüfen

Assessment of current approaches of starting dose selection and dose escalation for oncology biologics in first-in-patient trials

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e14093-e14093

2020

Link zum Volltext

Verfügbarkeit prüfen

Rethinking about the dose limiting toxicities (DLTs): They can be equivocal

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3064-3064

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT112: Initial results from a Phase 1 trial of a first-in-class pan-CDC-like kinase inhibitor (SM08502) with proof of mechanism in subjects with advanced solid tumors

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT112-CT112

2021

Link zum Volltext

Verfügbarkeit prüfen

A multicenter, randomized, double-blind, placebo-controlled phase III study of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab versus placebo in combination with rituximab in patients with treatment-naive follicular lymphoma (PERSPECTIVE)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS7576-TPS7576

2017

Link zum Volltext

Verfügbarkeit prüfen

Farnesyl Transferase Inhibitors Enhance Death Receptor Signals and Induce Apoptosis in Multiple Myeloma Cells

Leukemia & lymphoma, 2003-12, Vol.44 (12), p.2123-2134

2003

Link zum Volltext

Verfügbarkeit prüfen

Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2574-2574

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(38)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Humans
(20)
Oncology
(14)
Adult
(8)
Aged
(8)
Biological And Medical Sciences
(8)
Female
(8)
Male
(8)
Medical Sciences
(8)
Middle Aged
(8)
Hematology
(7)
Aged, 80 And Over
(6)
Dose-Response Relationship, Drug
(6)
Agammaglobulinaemia Tyrosine Kinase
(5)
Animals
(5)
Antineoplastic Agents
(5)
Antineoplastic Agents - Administration & Dosage
(5)
Cell Line, Tumor
(5)
Hematologic And Hematopoietic Diseases
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

Ibrutinib‐associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia

Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia

Characterization of a R115777-Resistant Human Multiple Myeloma Cell Line with Cross-Resistance to PS-341

A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors

RAS and Leukemia: From Basic Mechanisms to Gene-Directed Therapy

Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: Learnings from a survey of approved drugs

Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells

R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways

The Pan-Clk/Dyrk Inhibitor Cirtuvivint (SM08502) Exposes Mechanistic Underpinnings of Alternative Splicing As a Therapeutic Vulnerability in Heme Malignancies

Assessment of current approaches of starting dose selection and dose escalation for oncology biologics in first-in-patient trials

Rethinking about the dose limiting toxicities (DLTs): They can be equivocal

Abstract CT112: Initial results from a Phase 1 trial of a first-in-class pan-CDC-like kinase inhibitor (SM08502) with proof of mechanism in subjects with advanced solid tumors

A multicenter, randomized, double-blind, placebo-controlled phase III study of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab versus placebo in combination with rituximab in patients with treatment-naive follicular lymphoma (PERSPECTIVE)

Farnesyl Transferase Inhibitors Enhance Death Receptor Signals and Induce Apoptosis in Multiple Myeloma Cells

Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors

Suchergebnisse filtern